| アブストラクト | BACKGROUND: During the 2019 coronavirus disease (COVID-19) pandemic, although patients were advised to continue using angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), it remains unclear whether the pandemic influenced the occurrence of adverse reactions to these drugs. This study aims to analyze and compare changes in ACEIs and ARBs adverse events before and during the COVID-19 pandemic, exploring its potential impact on the safety of these medications. METHODS: We used real-world data to explore the impact of the COVID-19 pandemic on adverse events related to ACEIs and ARBs. RESULTS: During the pandemic, ACEI-related adverse events (70 cases) and ARB-related adverse events (7 cases) showed increased reporting rates and RORs, with a notable rise in ACEI-related ear and labyrinth disorders. Additionally, 170 new adverse event signals were detected for ACEIs (8 with significantly increased risk) and 191 signals for ARBs (2 with significantly increased risk). CONCLUSIONS: This study, based on real-world data, revealed significant signals indicating that ACEI use during the COVID-19 pandemic may have increased the risk of renal adverse events and ear labyrinth diseases. The study emphasized the need for increased caution when using ACEIs and ARBs during the pandemic. |
|---|
| 投稿者 | Qiu, Hui; He, Li; Zhou, Jianzhu; Feng, Zeying; Ye, Ling; Li, Tong; Huang, Xin; Huang, Longjian; Guo, Chengjun; Chen, Shaojun; Guo, Chengxian |
|---|
| 組織名 | Center of Clinical Pharmacology The Third Xiangya Hospital, Central South;University, Changsha, Hunan, China.;Department of Pediatrics, The Third Xiangya Hospital of Central South University,;Changsha, China.;Clinical Trial Institution Office, Liuzhou Hospital of Guangzhou Women and;Children's Medical Center, Liuzhou, China.;Department of Clinical Pharmacology, Xiangya Hospital, Central South University,;Changsha China.;Institute of Clinical Pharmacology, Central South University, Hunan Key;Laboratory of Pharmacogenetics, Changsha China.;Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry;of Education, Changsha China.;National Clinical Research Center for Geriatric Disorders, Xiangya Hospital,;West Guangxi Key Laboratory for Prevention and Treatment of High-Incidence;Diseases, Youjiang Medical University for Nationalities, Baise, China.;School of Applied Mathematics, Guangdong University of Technology, Guangzhou,;China.;Department of Medical Oncology, The Fourth Affiliated Hospital of Guangxi Medical;University, Liuzhou, China. |
|---|
